Acceleron Pharma Science & Pipeline

Science & Pipeline

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis.

Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.


Hematology

Hematology

REBLOZYL®
(luspatercept-aamt)

Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp
REBLOZYL® (luspatercept-aamt)
Beta-Thalassemia**
Beta-Thalassemia**
Myelodysplastic Syndromes**
Myelodysplastic
Syndromes**
luspatercept-aamt
luspatercept-aamt
Beta-Thalassemia

non-transfusion dependent

Beta-Thalassemia

non-transfusion dependent

BEYOND Trial*BEYOND Trial*BEYOND Trial*
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
COMMANDS Trial*COMMANDS Trial*COMMANDS Trial*
Myelofibrosis
Myelofibrosis
INDEPENDENCE Trial (planned)*INDEPENDENCE Trial (planned)*INDEP Trial (planned)*

* Bristol Myers Squibb-sponsored

** Reblozyl is approved in the United States for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions, and for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). It is not approved for any other use in the United States, or for any use in any other country.